Trial of an Injectable Biologic and U0279 as Combination Therapy for Severe Plaque-Type Psoriasis

Inclusion Criteria:

• Male or female subjects 18 years of age or older.
• Surgically sterile females. Females who have had a hysterectomy or completed menopause are allowed.
• Affected Body Surface Area with psoriasis of ≥10%.
• Psoriasis Global Assessment rating of "moderate to severe" or "severe".
• Achieved mild to moderate improvement after receiving an injectable biologic therapy for at least 12 weeks.
• A PASI score of ≥ 50 and ≤75
• Capable of understanding and willing to provide signed and dated written voluntary informed consent (and any local or national authorization requirements) before any protocol specific procedures are performed

Exclusion Criteria:

• Understand that the sponsor can not pay for the an injectable biologic therapy during the course of the study; be willing to pay out of pocket or secure payment through their private health insurance for an injectable biologic.
• History of systemic infection, or other conditions that may interfere with study evaluations or may increase risk for participation. such as, tuberculosis, human immunodeficiency virus (HIV), hepatitis; congestive heart failure or demyelinating disorder.
• Used of prohibited medications or therapies